Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published in The Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news